Orthotopic Tumor Models

Tumor growth is a complex process, influenced by multiple internal and external factors. One factor that can have a significant impact is the tumor implantation site: subcutaneous or orthotopic. Subcutaneous tumors have the advantage of being easy to implant and palpable. Orthotopic tumors enable us to study the tumor in a more relevant environment providing a solution that more closely mimics the progression of human disease.

Advantages of Orthotopic Implantation:

  • Provides a tumor microenvironment that recapitulates true tumor growth
  • Allows for the evaluation of metastatic potential from the original tumor
  • Offers the ability to track therapeutic responses
  • Can be combined with imaging for in vivo and ex vivo analysis

TD2 has developed a comprehensive library of orthotopic models in mouse and human cell lines (Figure 1) at various implantation sites.

Figure 1: Site and cell lines available for orthotopic implantation.

Site and cell lines available for orthotopic implantation

Learn more about our Orthotopic Tumor Models services.

Contact our experts to help advance your orthotopic tumor models with our trusted preclinical research services.

Orthotopic models available:

Syngeneic Lines

Intrabladder MBT-2, MB49
Intracranial GL261
Intrahepatic CT-26-luc
Intrarenal RENCA
Intrapancreatic Pano2
Intrathoracic LL2-luc (In development)
Mammary Fat Pad 4T1, 4T1-luc, EMT6, E0771
Ovarian Ascites ID8-luc
IP Disseminated Colon-26-luc
IV Disseminated B16-F10-luc

Figure 2: Survival of orthotopic intrapancreatic
implanted Pan02 in C57BL/6 mice (n=10 mice)
Response to: aPD-1 dosed Q4D x 5

Xenograft Lines

Intracranial BT-142, BT-474-luc, U251, U251-luc,
U87-MG, U87-MG-luc, NCI-H1975-luc,
Intrahepatic Hep3B, Huh-7-luc
Intrapancreatic BxPC3, BxPC3-luc, AsPC-1, AsPC-1-fluc,
Panc-1-luc, HPAF-II-luc
Intrathoracic NCI-H460-luc
IP Disseminated HCT-116-luc, SK-OV-3-luc, Cal-27-fluc,
Mammary Fat Pad BT-474, HCC70, MDA-MB-231,
Ovarian Ascites A2780, A2780CP, ES-2, OVCAR-8

Figure 3: Survival of U87-MG after orthotopic intracranial injection
in Nu/Nu mice (n=10). Response to: Temodar dosed Days 2-5 and Lomustine dosed Days 2, 9.

Survival of orthotopic intrapancreatic

Pan02 Syngeneic Orthotopic Pancreatic Tumor Model

Survival of U87-MG after orthotopic intracranial injection

U87-MG Xenograft Orthotopic Glioblastoma Tumor Model

Comprehensive Preclinical Services

Regardless of the development question, TD2 has the specialized model you need to move your drug forward. Clients have access to humanized models, induction models, as well as specialty surgical and orthotopic models. We specialize in all areas of oncology and work diligently to understand your therapeutics’ mechanism of action. We match that with clinical development strategies for an efficient path forward.

Comprehensive Preclinical Services


Work with a team who believes in your research as much as you do.

Are you ready to start your preclinical Adoptive Cell Transfer Therapy studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.